Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-10-31

Summary

BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged 18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on your recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.

• Phase: PHASE3

Details

• Lead Sponsor: Christian Medical College and Hospital, Ludhiana, India
• Collaborators: All India Institute of Medical Science, Guwahati; All India Institute of Medical Science, New Delhi; All India Institute of Medical Science, Patna, Bihar, India; All India Institute of Medical Sciences, Bhubaneswar; All India Institute of Medical Sciences, Bilaspur; All India Institute of Medical Sciences, Raebareli, UP; Amrita Institute of Medical Sciences & Research Center; Bangur Institute of Neurosciences Kolkata; Baptist Christian Hospital, Tezpur, India; Bharati Vidyapeeth DTU Medical College Pune, India; Christian Medical College, Vellore, India; Dr. Ramesh Cardiac and Multispecialty Hospital Guntur, India; Excelcare Hospitals Guwahati; Government General Hospital Guntur, India; Government Medical College Trivandrum, India; Government Medical College, Anantnag, India; Guru Gobind Singh Medical College & Hospital; Indian Council of Medical Research; Institute of Human Behaviour and Allied Sciences Delhi; Institute of Medical Sciences of the Banaras Hindu University, India; Jaiswal Multispeciality Hospital And Neuro Institute, Kota; Kasturba Medical College; KG Hospital and Post Graduate Medical Institute Coimbatore, India; KIMS-SUNSHINE Hospital, Hyderabad, India; King George's Medical University, Lucknow, India; KLE'S Dr Prabhakar Kore Hospital & MRC Balgaum; Lalitha Super Specialities Hospital; Manipal Group of Hospitals (Eastern Region), Kolkata, India; Narayana Medical College & Hospital; P. D. Hinduja Hospital and Medical Research Centre; PBM Hospital Bikaner, India; Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India; Rangaraya Medical College; Renova Institute of Neurological Sciences (RINS); Renova Century Hospital Hyderabad; Sahyadri Superspeciality Hospital, Nasik; Santokba Durlabhji Memorial Hospital; Shri Maharaja Hari Singh Hospital; Sree Chitra Tirunal Institute for Medical Sciences & Technology; Sri Balaji Institute of Medical Sciences, Raipur, Chhattisgarh, India; St. Stephen's Hospital, Delhi; Tirunelveli Medical College, Tirunelveli, India
• Treatments: Aspirin